Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
13 studies found for:    "NJMS" OR "New Jersey Medical School" | Open Studies | "Acquired Immunodeficiency Syndrome"
Show Display Options
Rank Status Study
1 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
2 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
3 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
4 Recruiting Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
5 Recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
6 Recruiting Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive ART
Condition: HIV-1 Infection
Intervention: Drug: Sirolimus
7 Recruiting Consent for Use of Stored Patient Specimens for Future Testing
Condition: HIV Infections
8 Recruiting Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Condition: HIV Infections
Intervention: Drug: Raltegravir
9 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
10 Recruiting Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Condition: HIV-1 Infection
Interventions: Drug: Visibiome;   Drug: Placebo
11 Recruiting Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
Condition: HIV/AIDS
12 Recruiting Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Condition: HIV-1 Infection
Interventions: Device: Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing);   Drug: Efavirenz;   Drug: Atazanavir/Ritonavir
13 Recruiting Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
Condition: Antiretroviral Toxicity

Indicates status has not been verified in more than two years